Hidden diversity in plain sight: four new species of Nemesia (Araneae: Mygalomorphae) from the Córdoba Province of Spain

Posted by
  Hidden diversity in plain sight: four new species of Nemesia (Araneae: Mygalomorphae) from the Córdoba Province of Spain Abstract A taxonomic revision of the species of Nemesia Audouin, 1826, distributed in the vicinity of Córdoba City, southern Spain, is presented. Four new species are described: Nemesia morana sp. nov. (female), N. kodama sp. nov. (male and female), N. rosae sp. nov. (male and female), and N. tamajoni sp. nov. (male and female). These species are distinguished by distinct morphological characters, including the shape of the spermathecae, palpal bulbs, and spinnerets, as well as by burrow architecture. Fieldwork was conducted across two of the three major habitat types in the region—the humid, forested mountains of Sierra Morena and the croplands and riparian forests of the Guadalquivir Valley—while the third, the “campiña”, which is mainly composed of agricultural landscapes, remains poorly explored. Sampling methods included pitfall trapping and the direct e...

Biofactories Applied to Future Antivenom Production

Posted by

 

Image Credit: By Ssiltane - Own work, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=52242648


Biofactories Applied to Future Antivenom Production

Abstract

Background: Accidents caused by the Loxosceles laeta spider constitute a health problem in South America. Envenomation can lead to severe systemic manifestations, eventually compromising the patient’s life. Most regional health authorities consider antivenom administration the basis of effective treatment in the most serious cases. The availability of spider venom is the primary bottleneck for antivenom production. Herein, we present a novel biotechnological approach, based on the expression of recombinant versions of the most relevant toxin in loxoscelism, sphingomyelinase D (SphD), in insect larvae (Spodoptera frugiperda). 

Methods: We produced two versions of SphD: one conserving its biological activities (wtSphD) and a second alternative that was designed to be genetically detoxified (dSphD). Two horses were subjected to three consecutive hyperimmunization cycles with dSphD. The horses’ plasma was extracted at the end of each cycle and used to produce Active Pharmaceutical Ingredients (APIs) of antivenoms at a pilot scale. 

Results: Dermonecrotic activity of wtSphD was completely neutralized with the sera obtained from one horse and partially with that of the other. In contrast, the APIs derived in both cases completely neutralized wtSphD dermonecrotic activity. Direct hemolysis of human red blood cells by wtSphD was also neutralized by sera and APIs. Conclusions: These results show venom replacement or complementation potential by recombinant dSphD produced in this novel platform.

Rodriguez, M. S., Macoretta, C. L., Smith, I., Wolman, F. J., Targovnik, A. M., Miranda, M. V., & Fingermann, M. (2026). Biofactories Applied to Future Antivenom Production. Journal of Pharmaceutical and BioTech Industry, 3(2). https://doi.org/10.3390/jpbi3020008